In addition, IL-4-binding fusion protein APG598 and IL-4R antagonist APG201 (R121D/Y124D) improved the chemosensitivity of Hodgkin lymphoma cells [141], which indicates that the combination of classical chemotherapy with IL-4/IL-13 antagonists may improve the efficacy of the both in cancer treatments. Here, IL4R is linked to cancer.